latest news releases from the newsroom
Penwest Pharmaceuticals Co.
Penwest Sends Letter to Shareholders On Financial, Business and Corporate Governance Developments
DANBURY, Conn., March 12, 2009 (GLOBE NEWSWIRE) -- Penwest Pharmaceuticals Co. (Nasdaq:PPCO) today sent a letter to its shareholders in which the Company provided an update on its recent financial and business performance and discussed corporate governance matters, including a threatened proxy contest against the Company and the adoption by its Board of Directors of a limited-duration shareholder rights plan.
BSD Medical Corporation
BSD Medical Corp.: Lecture At Surgical Oncology Conference Reports Near Doubling of Disease-Free Survival When Hyperthermia Therapy Was Added to Chemotherapy in Treating Sarcoma Cancer Patients
SALT LAKE CITY, March 12, 2009 (GLOBE NEWSWIRE) -- BSD Medical Corp. (Nasdaq:BSDM) announced today that Professor Rolf Issels, M.D. Ph.D. of the Munich University Medical School in Germany delivered an invited lecture entitled, "Regional Hyperthermia Combination with Chemotherapy for High Risk Soft Tissue Sarcoma" at The Society of Surgical Oncology conference recently concluded at the Phoenix Convention Center in Arizona. Dr. Issels, as the lead investigator for this major study, presented the results of a 341 patient randomized Phase III clinical trial that evaluated the benefit of adding hyperthermia therapy to chemotherapy for the treatment of cancer. The study was conducted at nine major European cancer treatment institutions and at Duke University Medical Center in the USA. The study demonstrated that both disease-free survival time and local tumor progression free survival time nearly doubled for patients with locally advanced, high-grade soft tissue sarcomas when hyperthermia therapy, using the BSD-2000 hyperthermia system, was added to chemotherapy, as compared to patients who received chemotherapy alone.